Literature DB >> 16540489

Diabetic cataract removal: postoperative progression of maculopathy--growth factor and clinical analysis.

J I Patel1, P G Hykin, I A Cree.   

Abstract

BACKGROUND: Diabetic cataract extraction can be frequently complicated by macular oedema, progression of retinopathy, or development of iris neovascularisation. The pathogenesis of these complications may be the result of changes in the concentration of angiogenic and anti-angiogenic cytokines in the immediate postoperative period. The study aims to prospectively analyse this.
METHODS: Uneventful phacoemulsification with intraocular lens implant was performed in seven eyes of six patients with diabetic retinopathy ranging from severe non-proliferative to quiescent proliferative. Patients were reviewed 1 day, 1 week, 1 month, and 3 months after surgery with fundus fluorescein angiography (FFA) and aqueous sampling. Each sample was analysed for VEGF, HGF, Il-1 beta (pg/ml), and PEDF (microg/ml) by sandwich ELISA.
RESULTS: Clinically significant macular oedema (CSMO) occurred in one patient although increased macular hyperfluorescence occurred in three patients on FFA at 1 month. VEGF 165 concentration increased 1 day after surgery from a median baseline of 68 pg/ml (range 22-87 pg/ml) to 723 pg/ml (range 336-2071) at day 1. By 1 month it had decreased to 179 (range 66-811 pg/ml). HGF concentrations steadily increased over the month while IL-1 beta and PEDF concentrations demonstrated an acute rise on day 1 after surgery and then IL-1beta returned to baseline concentrations while PEDF decreased to below baseline.
CONCLUSION: These results confirm altered concentrations of angiogenic and antiangiogenic growth factors after cataract surgery, which may induce subclinical and clinical worsening of diabetic maculopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540489      PMCID: PMC1860210          DOI: 10.1136/bjo.2005.087403

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  11 in total

1.  Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells.

Authors:  W G Jiang; T A Martin; K Matsumoto; T Nakamura; R E Mansel
Journal:  J Cell Physiol       Date:  1999-11       Impact factor: 6.384

2.  Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy.

Authors:  A Cantón; R Burgos; C Hernández; C Mateo; R M Segura; J Mesa; R Simó
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

3.  Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts.

Authors:  Yoshihiro Kida; Makoto Kobayashi; Takao Suzuki; Akira Takeshita; Yoshimasa Okamatsu; Sigemasa Hanazawa; Toshikazu Yasui; Kohji Hasegawa
Journal:  Cytokine       Date:  2004-12-02       Impact factor: 3.861

4.  VEGF-initiated blood-retinal barrier breakdown in early diabetes.

Authors:  T Qaum; Q Xu; A M Joussen; M W Clemens; W Qin; K Miyamoto; H Hassessian; S J Wiegand; J Rudge; G D Yancopoulos; A P Adamis
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-09       Impact factor: 4.799

5.  Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown.

Authors:  J D Luna; C C Chan; N L Derevjanik; J Mahlow; C Chiu; B Peng; T Tobe; P A Campochiaro; S A Vinores
Journal:  J Neurosci Res       Date:  1997-08-01       Impact factor: 4.164

6.  Production of hepatocyte growth factor from human lung microvascular endothelial cells induced by interleukin-1beta.

Authors:  T Morisako; K Takahashi; K Kishi; T Kiguchi; R Mikami; K Kobayashi; H Yagyu; H Nakamura; K T Matsuoka
Journal:  Exp Lung Res       Date:  2001-12       Impact factor: 2.459

7.  Severe diabetic retinopathy after cataract surgery.

Authors:  H Schatz; D Atienza; H R McDonald; R N Johnson
Journal:  Am J Ophthalmol       Date:  1994-03-15       Impact factor: 5.258

8.  Upregulation of vascular endothelial growth factor (VEGF) in the retinas of transgenic mice overexpressing interleukin-1beta (IL-1beta) in the lens and mice undergoing retinal degeneration.

Authors:  S A Vinores; W-H Xiao; R Zimmerman; S M Whitcup; E F Wawrousek
Journal:  Histol Histopathol       Date:  2003-07       Impact factor: 2.303

9.  Extracapsular cataract surgery with lens implantation in diabetics with and without proliferative retinopathy.

Authors:  I A Cunliffe; D W Flanagan; N D George; R J Aggarwaal; A T Moore
Journal:  Br J Ophthalmol       Date:  1991-01       Impact factor: 4.638

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

View more
  20 in total

1.  [The primary objective in macular hole surgery. Ultrastructural features of the vitreomacular interface].

Authors:  R G Schumann; M M Schaumberger; M Rohleder; C Haritoglou; A Kampik; A Gandorfer
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.059

2.  Benchmarking cataract surgery outcomes in an ethnically diverse and diabetic population: final post-operative visual acuity and rates of post-operative cystoid macular oedema.

Authors:  K Oyewole; F Tsogkas; M Westcott; S Patra
Journal:  Eye (Lond)       Date:  2017-06-23       Impact factor: 3.775

Review 3.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

4.  Comparison of VEGF level in tears post phacoemulsification between non-proliferative diabetic retinopathy and non-diabetic patients.

Authors:  Azman Azhan; Embong Zunaina; Mohamed Mahaneem; Ab Hamid Siti-Azrin
Journal:  J Diabetes Metab Disord       Date:  2021-08-20

5.  Bevacizumab in vitreous haemorrhage secondary to radiation retinopathy.

Authors:  Javier Antonio Montero; Giovanni Yanez-Castro; Maria Eugenia Sanchis-Merino; Jose Maria Ruiz-Moreno
Journal:  BMJ Case Rep       Date:  2014-02-07

Review 6.  Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.

Authors:  Winfried M Amoaku; Faruque Ghanchi; Clare Bailey; Sanjiv Banerjee; Somnath Banerjee; Louise Downey; Richard Gale; Robin Hamilton; Kamlesh Khunti; Esther Posner; Fahd Quhill; Stephen Robinson; Roopa Setty; Dawn Sim; Deepali Varma; Hemal Mehta
Journal:  Eye (Lond)       Date:  2020-06       Impact factor: 3.775

7.  Combined intravitreal bevacizumab with phacoemulsification in visually significant cataract and visually significant exudative maculopathy.

Authors:  Ahmad Mansour; Ziad F Bashshur; Tarek A Sibai; Abla Mehio-Sibai; Rola N Hamam
Journal:  Oman J Ophthalmol       Date:  2011-01

8.  Cataracts in diabetic patients: a review article.

Authors:  Mohammad-Ali Javadi; Siamak Zarei-Ghanavati
Journal:  J Ophthalmic Vis Res       Date:  2008-01

Review 9.  Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant.

Authors:  Zafer Cebeci; Nur Kir
Journal:  Diabetes Metab Syndr Obes       Date:  2015-11-16       Impact factor: 3.168

10.  Comparison of Perioperative Ranibizumab Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery.

Authors:  Erhan Yumuşak; Kemal Örnek
Journal:  J Ophthalmol       Date:  2016-07-14       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.